| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,019 |
5,034 |
$142K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,302 |
3,884 |
$67K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
6,161 |
4,668 |
$42K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,929 |
1,496 |
$22K |
| 99215 |
Prolong outpt/office vis |
306 |
201 |
$9K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
131 |
70 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
49 |
36 |
$4K |
| 64493 |
|
82 |
41 |
$3K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
275 |
212 |
$2K |
| 80306 |
|
77 |
51 |
$876.82 |
| 96127 |
|
1,158 |
736 |
$760.61 |
| 27096 |
|
28 |
13 |
$585.84 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
983 |
521 |
$446.34 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
80 |
38 |
$395.54 |
| 64494 |
|
58 |
28 |
$229.75 |
| 96132 |
|
56 |
43 |
$195.05 |
| 64495 |
|
58 |
28 |
$165.00 |
| 96138 |
|
46 |
33 |
$52.29 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
261 |
252 |
$0.21 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
262 |
253 |
$0.21 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
262 |
253 |
$0.21 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
262 |
253 |
$0.21 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
262 |
253 |
$0.21 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
152 |
149 |
$0.14 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
109 |
106 |
$0.10 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
31 |
28 |
$0.02 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
16 |
14 |
$0.01 |
| 3288F |
|
260 |
251 |
$0.00 |
| 0518F |
|
260 |
251 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
75 |
37 |
$0.00 |